Loncar China Biopharma ETF

  • CHNA


, ,

Rank

Rank Universe
9 7

Summary

The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies outside the United States.

The sub-adviser’s investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

As part of its strategy, the fund employs a passive More

Webiste

Price

  • $ 13.54 ( -2.24 )
  • Oct 19, 2023
    Last Close
  • Net Assets
  • 52-Week High/Low
  • $0 - $0

  • Expense Ratio
  • -

Performance

YTD

0%

3 Year

-55.89%

5 Year

-32.84%

Best

66.79%

2009

Worst

-63.36%

2018

Documents

Prospectus

link

Annual Reports

link

Fact Sheet

NAV

Annual Return

Alpha - CHNA and S&P